Fri, April 1, 2022

Silvan Tuerkcan Maintained (TSHA) at Buy with Decreased Target to $36 on, Apr 1st, 2022

Silvan Tuerkcan of JMP Securities, Maintained "Taysha Gene Therapies, Inc." (TSHA) at Buy with Decreased Target from $44 to $36 on, Apr 1st, 2022.

Silvan has made no other calls on TSHA in the last 4 months.



There are 3 other peers that have a rating on TSHA. Out of the 3 peers that are also analyzing TSHA, 0 agree with Silvan's Rating of Hold.



These are the ratings of the 3 analyists that currently disagree with Silvan


  • Jack Allen of "Baird" Initiated at Buy and Held Target at $26 on, Wednesday, March 9th, 2022
  • Yanan Zhu of "Wells Fargo" Initiated at Buy and Held Target at $25 on, Tuesday, March 1st, 2022
  • Debjit Chattopadhyay of "Guggenheim" Initiated at Strong Buy and Held Target at $28 on, Thursday, December 16th, 2021